Skip to main content

Advertisement

Table 2 Baseline characteristics of hemodialysis patients presented as groups according to MBL levels

From: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients

MBL range (ng/mL) Patients P* < 0.001 R P#
All (n = 107) MBL low 319 <  ng/mL (n = 26) MBL high 319 ≥  ng/mL (n = 81)
821[319–1477] 98[33–146] 1290[671–1848]
Demographics
Age, years 62.5 ± 15.6 65.3 ± 12.1 61.56 ± 16.6 0.3 –0.26 0.007
Male gender, n (%) 71 (66) 17 (65) 54 (67) 1.0   
Current diabetes, n (%) 25 (24) 9 (35) 16 (20) 0.2   
Hypertension, n (%) 85 (84) 22 (88) 63 (83) 0.8   
Cardiovascular history, n (%) 26 (25) 9 (35) 15 (19) 0.1   
BMI, kg/m2 25.8 ± 4.4 27.0 ± 4.5 25.4 ± 4.4 0.1 –0.03 0.8
Hemodialysis
Dialysis vintage, months 25.5 [8.5–52.3] 18.2 [7.0–47.7] 32.8 [9.1–53.3] 0.2 –0.01 0.9
Primary renal disease, n (%)
Hypertension 18 (17) 4 (15) 14 (17) 1.0   
Diabetes 14 (13) 5 (19) 9 (11) 0.3   
ADPKD 13 (12) 3 (12) 10 (12) 1.0   
FSGS 9 (8) 4 (15) 5 (6) 0.2   
IgA nephropathy 4 (4) 0 (0) 4 (5) 0.6   
Chronic pyelonephritis 3 (3) 0 (0) 3 (4) 1.0   
Glomerulonephritis 13 (12) 2 (8) 11 (14) 0.7   
Other diagnoses 16 (16) 6 (23) 10 (12) 0.2   
Unknown 17 (16) 2 (8) 15 (19) 0.2   
Ultrafiltration volume, L 2.55 ± 0.78 2.54 ± 0.82 2.56 ± 0.78 0.9 –0.01 0.9
Ultrafiltration rate, ml/kg/h 8.56 ± 2.63 7.81 ± 2.39 8.80 ± 2.67 0.1 0.04 0.7
Systolic blood pressure
Predialysis, mmHg 140.4 ± 25.1 144.7 ± 26.4 139.1 ± 24.7 0.3 –0.17 0.08
Postdialysis, mmHg 131.8 ± 25.6 136 ± 24.3 130.4 ± 26.0 0.4 –0.24 0.02
Heart rate
Predialysis, bpm 73 [63–82] 71 [62–82] 74 [64–82] 0.3 0.11 0.3
Postdialysis, bpm 79 [69–87] 75 [65–86] 79 [69–88] 0.4 0.13 0.2
Kidney transplant, n (%) 21 (20) 4 (15) 17 (21) 0.8   
Laboratory measurements
Hematocrit,  % 34.9 ± 3.8 34.5 ± 4.1 35.0 ± 3.7 0.6 0.04 0.7
HbA1c, mmol/mol 5.68 ± 0.98 5.80 ± 0.97 5.63 ± 0.98 0.5 –0.15 0.2
Albumin, g/L 39 [37–42] 39 [37–42] 39 [37–42] 0.9 0.01 0.9
pH 7.37 [7.34–7.39] 7.37 [7.32–7.39] 7.37 [7.34–7.39] 0.7 0.05 0.6
Calcium, mmol/L 2.31 ± 0.16 2.31 ± 0.15 2.32 ± 0.16 0.9 0.03 0.7
Phosphate, mmol/L 1.67 ± 0.53 1.82 ± 0.47 1.65 ± 0.54 0.2 –0.00 0.9
hsCRP, mg/L 6.7 [2.8–10.9] 6.1 [1.4–12.0] 6.7 [3.0–10.9] 0.7 0.10 0.3
Medication
Aspirin, n (%) 57 (54) 11 (42) 46 (64) 0.3   
Calcium channel blockers, n (%) 14 (13) 3 (12) 11 (14) 1.0   
β-Blocker, n (%) 61 (57) 18 (69) 43 (53) 0.2   
ACE inhibitor, n (%) 10 (10) 3 (12) 7 (9) 0.7   
AT2-receptor antagonists, n (%) 14 (13) 2 (8) 12 (15) 0.5   
Statin, n (%) 20 (19) 5 (19) 15 (19) 1.0   
Diuretics, n (%) 8 (8) 3 (12) 5 (6) 0.4   
  1. Italic values used to show which statistical testing was significant (below 0.05)
  2. BMI body mass index; ADPKD autosomal dominant polycystic kidney disease; FSGS focal segmental glomerulosclerosis; HbA1c Hemoglobin A1c; pH potential hydrogen; hsCRP high sensitive C-reactive protein; ACE inhibitor angiotensin-converting-enzyme inhibitor; AT2 receptor antagonists, Angiotensin II receptor antagonists
  3. P* indicates P-value for the difference in baseline characteristics between the MBL groups, tested by Student’s t-Test or Mann–Whitney U test for continuous variables and with χ2 test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; # P indicates the corresponding P-value
  4. Data are presented as mean ± SD or median [IQR]